BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $EXEL readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05678673-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:STELLAR-304 readout (P3) · Exelixis $EXEL
DESCRIPTION:Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanc
 ed or Metastatic Non-Clear Cell Renal Cell Carcinoma\n\nPrimary completion
  date: 2026-12-15 (estimated)\nOriginally planned: 2025-07 (+17.5 months)\
 nPhase 3 · Oncology · Non-Clear Cell Renal Cell Carcinoma\nEnrollment: 3
 17 · Sites: 163\n\nPrimary completion = last participant's primary-endpoi
 nt data collected\; topline results usually follow weeks to months later. 
 Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://tr
 ialsonar.netlify.app/radar.html?nct=NCT05678673\nhttps://clinicaltrials.go
 v/study/NCT05678673
URL:https://datacutoff.com/radar.html?nct=NCT05678673
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
